Overview

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

Status:
RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB subjects will increase their life span.
Phase:
PHASE2
Details
Lead Sponsor:
Stanford University
Collaborator:
Epidermolysis Bullosa Research Partnership